Treatment for advanced solid tumors with CLDN18.2 expression

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the safety and efficacy of SHR-A1904 in patients with CLDN18.2-positive advanced solid tumors. It consists of a Phase Ib dose escalation and efficacy extension phase, followed by a Phase III randomized study comparing SHR-A1904 combined with chemotherapy and immunotherapy against standard chemotherapy and immunotherapy. The goal is to determine the recommended dose and population for further studies. Participants will be closely monitored for safety and treatment response.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 18 to 75 years old (including boundary values);
2. Volunteer to participate in this clinical study and sign informed consent;
3. ECOG score 0-1;
4. Expected survival ≥3 months;
5. Pathologically confirmed locally advanced unresectable or metastatic solid tumors;
6. positive CLDN18.2 expression in tumor tissue;
7. There is at least one measurable lesion that meets the RECIST 1.1 criteria;
8. Adequate bone marrow and organ function.

Exclusion Criteria:

1. Plan to receive any other antitumor therapy during this trial; Received other investigational drugs or treatments that are not on the market within 4 weeks prior to the first administration; Anti-tumor therapy, such as chemotherapy, radiotherapy, biotherapy, targeted therapy or immunotherapy, was received within 4 weeks before the first administration of the study drug. Palliative radiotherapy or local therapy within 2 weeks before the first administration of the study drug; Had major surgery other than diagnosis or biopsy within the 4 weeks prior to the first administration or randomization and required elective surgery during the trial.
2. HER2 expression in tumor tissue is positive.
3. The adverse reactions of previous anti-tumor therapy has not recovered to NCI-CTCAE v5.0 grade≤ 1.
4. Has ≥ grade 2 peripheral sensory neuropathy.
5. Has an allergic reaction to any of the components treated in this study, or are allergic to humanized monoclonal antibody products.
6. Has a history or current history of meningeal metastasis; or active brain metastases.
7. Presence of dysphagia or other factors affecting the use of oral medications.
8. Additional malignancy within the five years prior to the first administration or randomization.
9. Has an active autoimmune disease or a history of autoimmune disease.
10. Received systemic use of corticosteroids or other immunosuppressants for immunosuppressive effects within 14 days prior to the first administration or randomization.
11. Has a history of clinically significant lung disease.
12. Has serosal effusion ≥ grade 3 (based on NCI CTCAE5.0 criteria).
13. There was an active infection requiring systemic treatment within 2 weeks prior to the first administration or randomization.
14. A history of immunodeficiency, including a positive HIV test; Presence of active hepatitis B or hepatitis C.
15. People who have previously received allogeneic hematopoietic stem cell transplantation or organ transplantation.
16. Has severe cardiovascular and cerebrovascular diseases.
17. Gastrointestinal perforation and/or gastrointestinal fistula within the last 6 months prior to the first administration or randomization; Active gastrointestinal bleeding occurred 3 months before the first administration or randomization.
18. In the investigator's judgment, the subject has other factors that could have affected the study results or led to the forced termination of the study.

Where it's running

• Sun Yat-sen University Cancer Center
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Qi Shi
• Email: qi.shi.qs16@hengrui.com
• Phone: 0518-82342973

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Shrinkage-free combo in LS-SCLC: SHR-7787 plus SHR-1316

  This trial tests whether the combo of SHR-7787 and SHR-1316 can help adults with unresectable limited-stage small cell lung cancer after prior platinum-based chemo and radiation.

  Recruiting Phase 2 Shanghai Hengrui Pharmaceutical Co., Ltd. · Jinan, Shandong · NCT07798947

• SHR-3836 in Relapsed or Refractory Multiple Myeloma

  This phase 1 study tests SHR-3836 in adults with relapsed or refractory multiple myeloma to see if it can be given safely and what effects it has.

  Recruiting Phase 1 Shanghai Hengrui Pharmaceutical Co., Ltd. · Suzhou, Jiangsu · NCT07490613

• HRS-4642 with chemotherapy and immunotherapy for advanced pancreatic cancer

  This study tries adding HRS-4642 to standard chemotherapy and/or an immune therapy to see if it helps people with unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma.

  Recruiting Phase 1/2 Shanghai Hengrui Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07296341

• SHR-7787 combined with other anti-cancer drugs for malignant solid tumors

  This study will test whether giving SHR-7787 together with other anti-cancer medicines is safe and helps people with unresectable malignant solid tumors.

  Recruiting at 2 sites Phase 2 Shanghai Hengrui Pharmaceutical Co., Ltd. · Wuhan, Hubei and 1 other locations · NCT07268040

• SHR-A2102 combined with other anti-cancer therapies around surgery for resectable non-small cell lung cancer

  This trial will test SHR-A2102 given with other anti-cancer drugs around the time of surgery in adults with resectable non-small cell lung cancer.

  Recruiting Phase 2 Shanghai Hengrui Pharmaceutical Co., Ltd. · Guangzhou, Guangdong · NCT07229729

• SHR-7367 combined with other anti-cancer agents for adults with advanced solid tumors.

  This trial will test whether SHR-7367 given with standard anti-cancer drugs is safe and shows early signs of benefit in adults with advanced solid tumors.

  Recruiting Phase 1/2 Shanghai Hengrui Pharmaceutical Co., Ltd. · Tianjin, Tianjin Municipality · NCT07229586

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.